The Nobel committee in Stockholm announced on Monday, October 5, that the 2026 prize for physiology or medicine goes to three scientists whose discoveries gave science a way to switch individual nerve cells on and off with a beam of light. The prize goes to American Karl Deisseroth of Stanford University and Germans Peter Hegemann of Humboldt University in Berlin and Georg Nagel of the University of Würzburg. The three laid the groundwork for the method known today as optogenetics, which labs around the world use to turn specific neurons in a living brain on and off without touching the cells next to them.
The story starts in the early 1990s at the Max Planck Institute, where Hegemann tried to work out why the single-celled green alga Chlamydomonas finds its way toward light on its own. Working with Nagel, he found the answer: a protein on the edge of the cell called channelrhodopsin. When light hits it, the protein opens like a door and lets charged particles pass through the membrane, creating an electrical signal. Hegemann's lab found the first version, channelrhodopsin-1, and a year later Nagel showed that a second version, known as ChR2, opens differently and responds to blue light.
The idea that light could drive nerve cells is much older than the discovery itself. Biologist Francis Crick once said light would be the "ideal signal" for controlling neurons, though he admitted the idea was "quite far from reality" in his time. In the 1970s, physicist Richard Fork of Bell Laboratories published the first attempt to trigger a nerve with light in the journal Science, but he used the sea slug Aplysia, with no gene involved and no practical use. It took another generation of scientists before Hegemann, Nagel and Deisseroth turned that speculation into a working tool.
The breakthrough came in 2005, when Deisseroth inserted the channelrhodopsin gene into rat neurons grown in a lab dish and published the result in Nature Neuroscience. A flash of light made the cells fire a nerve signal in a fraction of a millisecond, with a precision no other method had offered before. Two years later, in 2007, his team repeated the experiment in the living brain of a mouse: an optical fiber inserted into the animal's skull carried blue light to neurons engineered to carry the gene for the light-sensitive protein, making them fire on command. The term "optogenetics" itself came into use in 2006.
The method gave scientists something they had lacked until then: a way to switch off one exact group of neurons and see what the brain does without them, instead of guessing from drugs or electrodes that stir up everything around them. Research teams used it to map which cells drive hunger, fear, aggression and social behavior. In 2012, for example, scientists used light to activate a specific group of neurons tied to a single fear memory in a mouse, proving that memory is stored in exact cells rather than spread across the whole brain. Nobel committee member Abdel El Manira said this gave researchers a "powerful tool" for a brain that "still holds countless mysteries."
14 years blind, then glasses with a camera
Optogenetics is still mainly a research tool, not a ready-made treatment, and that is why the laureates themselves speak carefully about its clinical side. The first clinical trial using the method aims to restore sight in people with retinitis pigmentosa, an inherited disease in which the eye's light-sensing cells slowly die. In one trial, doctors used gene therapy to insert a protein called ChrimsonR into optic nerve cells of a patient who had been blind for 14 years, then fitted him with special glasses carrying a camera that projects images straight onto those cells. After about five months of training, and then seven more, the man was able to spot, touch and count objects in front of him — something he could not do without the glasses. In a test with a notebook, he identified the object correctly 36 out of 39 times, and when counting cups he got just over half right. Similar trials are underway for cochlear implants in deafness, and labs are studying the same approach for Parkinson's, epilepsy and depression, so far only in animal studies or early-stage human trials.
The Nobel committee also added a warning: the ability to trigger a specific memory or feeling with a beam of light raises the question of where treatment ends and interference with the mind begins. Deisseroth himself talks about the discovery more as a scientist than as a healer. "What we're doing now is seeing how we can use this precision to find new treatments and approaches," he said.
The three laureates will split a prize fund of 12 million Swedish kronor, about $1.2 million, equally. The award ceremony is set for December 10 in Stockholm, the anniversary of Alfred Nobel's death. Hours after the announcement, Deisseroth said he was heading back to work in the lab: "We have a lot more that we want to find out."